Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA

Ruth A. Bryan, Zewei Jiang, Thomas Jandl, Julius Strauss, Wade R. Koba, Chukwuemeka Onyedika, Alfred Morgenstern, Frank Bruchertseifer, Alan L. Epstein, Ekaterina Dadachova

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Novel approaches to treatment of pancreatic cancer (PCa) are urgently needed. A chimeric monoclonal antibody (mAb) chTNT3 binds to single-strand DNA (ssDNA) and RNA released from the non-viable cells in fast growing tumors. Here the authors investigated whether radioimmunotherapy (RIT) using chTNT3 mAb radiolabeled with 213-Bismuth (<sup>213</sup>Bi) could be effective in treatment of experimental PCa. Methods: Two human PCa cell lines, Panc1 and MiaPaCa-2, were used for in vitro experiments. The xenografts in mice were established using MiaPaCa-2 cells. Therapy compared <sup>213</sup>Bi-chTNT3 (700 μCi) to gemcitabine or cisplatin, untreated controls and 'cold' chTNT3. Results: RIT abrogated the tumors growth while tumors in control groups grew aggressively. Chemotherapy was less effective than RIT and toxic to mice while RIT did not have any side effects. Conclusions: RIT with <sup>213</sup>Bi-chTNT3 was safe and effective in the treatment of experimental PCa in comparison with chemotherapy. This makes α-RIT targeting ssDNA a promising modality for further development.

Original languageEnglish (US)
Pages (from-to)1243-1249
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Radioimmunotherapy
Bismuth
Pancreatic Neoplasms
Antibodies
DNA
gemcitabine
Therapeutics
Monoclonal Antibodies
Drug Therapy
Neoplasms
Poisons
Heterografts
Cisplatin
RNA
Cell Line
Control Groups
Growth

Keywords

  • 213-Bismuth
  • cisplatin
  • gemcitabine
  • intracellular antigens
  • pancreatic cancer
  • radioimmunotherapy
  • single-strand DNA

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Medicine(all)

Cite this

Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. / Bryan, Ruth A.; Jiang, Zewei; Jandl, Thomas; Strauss, Julius; Koba, Wade R.; Onyedika, Chukwuemeka; Morgenstern, Alfred; Bruchertseifer, Frank; Epstein, Alan L.; Dadachova, Ekaterina.

In: Expert Review of Anticancer Therapy, Vol. 14, No. 10, 01.10.2014, p. 1243-1249.

Research output: Contribution to journalArticle

Bryan, RA, Jiang, Z, Jandl, T, Strauss, J, Koba, WR, Onyedika, C, Morgenstern, A, Bruchertseifer, F, Epstein, AL & Dadachova, E 2014, 'Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA', Expert Review of Anticancer Therapy, vol. 14, no. 10, pp. 1243-1249. https://doi.org/10.1586/14737140.2014.952285
Bryan, Ruth A. ; Jiang, Zewei ; Jandl, Thomas ; Strauss, Julius ; Koba, Wade R. ; Onyedika, Chukwuemeka ; Morgenstern, Alfred ; Bruchertseifer, Frank ; Epstein, Alan L. ; Dadachova, Ekaterina. / Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. In: Expert Review of Anticancer Therapy. 2014 ; Vol. 14, No. 10. pp. 1243-1249.
@article{237fce4797984d05900c0612810d82d5,
title = "Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA",
abstract = "Background: Novel approaches to treatment of pancreatic cancer (PCa) are urgently needed. A chimeric monoclonal antibody (mAb) chTNT3 binds to single-strand DNA (ssDNA) and RNA released from the non-viable cells in fast growing tumors. Here the authors investigated whether radioimmunotherapy (RIT) using chTNT3 mAb radiolabeled with 213-Bismuth (213Bi) could be effective in treatment of experimental PCa. Methods: Two human PCa cell lines, Panc1 and MiaPaCa-2, were used for in vitro experiments. The xenografts in mice were established using MiaPaCa-2 cells. Therapy compared 213Bi-chTNT3 (700 μCi) to gemcitabine or cisplatin, untreated controls and 'cold' chTNT3. Results: RIT abrogated the tumors growth while tumors in control groups grew aggressively. Chemotherapy was less effective than RIT and toxic to mice while RIT did not have any side effects. Conclusions: RIT with 213Bi-chTNT3 was safe and effective in the treatment of experimental PCa in comparison with chemotherapy. This makes α-RIT targeting ssDNA a promising modality for further development.",
keywords = "213-Bismuth, cisplatin, gemcitabine, intracellular antigens, pancreatic cancer, radioimmunotherapy, single-strand DNA",
author = "Bryan, {Ruth A.} and Zewei Jiang and Thomas Jandl and Julius Strauss and Koba, {Wade R.} and Chukwuemeka Onyedika and Alfred Morgenstern and Frank Bruchertseifer and Epstein, {Alan L.} and Ekaterina Dadachova",
year = "2014",
month = "10",
day = "1",
doi = "10.1586/14737140.2014.952285",
language = "English (US)",
volume = "14",
pages = "1243--1249",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA

AU - Bryan, Ruth A.

AU - Jiang, Zewei

AU - Jandl, Thomas

AU - Strauss, Julius

AU - Koba, Wade R.

AU - Onyedika, Chukwuemeka

AU - Morgenstern, Alfred

AU - Bruchertseifer, Frank

AU - Epstein, Alan L.

AU - Dadachova, Ekaterina

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: Novel approaches to treatment of pancreatic cancer (PCa) are urgently needed. A chimeric monoclonal antibody (mAb) chTNT3 binds to single-strand DNA (ssDNA) and RNA released from the non-viable cells in fast growing tumors. Here the authors investigated whether radioimmunotherapy (RIT) using chTNT3 mAb radiolabeled with 213-Bismuth (213Bi) could be effective in treatment of experimental PCa. Methods: Two human PCa cell lines, Panc1 and MiaPaCa-2, were used for in vitro experiments. The xenografts in mice were established using MiaPaCa-2 cells. Therapy compared 213Bi-chTNT3 (700 μCi) to gemcitabine or cisplatin, untreated controls and 'cold' chTNT3. Results: RIT abrogated the tumors growth while tumors in control groups grew aggressively. Chemotherapy was less effective than RIT and toxic to mice while RIT did not have any side effects. Conclusions: RIT with 213Bi-chTNT3 was safe and effective in the treatment of experimental PCa in comparison with chemotherapy. This makes α-RIT targeting ssDNA a promising modality for further development.

AB - Background: Novel approaches to treatment of pancreatic cancer (PCa) are urgently needed. A chimeric monoclonal antibody (mAb) chTNT3 binds to single-strand DNA (ssDNA) and RNA released from the non-viable cells in fast growing tumors. Here the authors investigated whether radioimmunotherapy (RIT) using chTNT3 mAb radiolabeled with 213-Bismuth (213Bi) could be effective in treatment of experimental PCa. Methods: Two human PCa cell lines, Panc1 and MiaPaCa-2, were used for in vitro experiments. The xenografts in mice were established using MiaPaCa-2 cells. Therapy compared 213Bi-chTNT3 (700 μCi) to gemcitabine or cisplatin, untreated controls and 'cold' chTNT3. Results: RIT abrogated the tumors growth while tumors in control groups grew aggressively. Chemotherapy was less effective than RIT and toxic to mice while RIT did not have any side effects. Conclusions: RIT with 213Bi-chTNT3 was safe and effective in the treatment of experimental PCa in comparison with chemotherapy. This makes α-RIT targeting ssDNA a promising modality for further development.

KW - 213-Bismuth

KW - cisplatin

KW - gemcitabine

KW - intracellular antigens

KW - pancreatic cancer

KW - radioimmunotherapy

KW - single-strand DNA

UR - http://www.scopus.com/inward/record.url?scp=84907549190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907549190&partnerID=8YFLogxK

U2 - 10.1586/14737140.2014.952285

DO - 10.1586/14737140.2014.952285

M3 - Article

C2 - 25156106

AN - SCOPUS:84907549190

VL - 14

SP - 1243

EP - 1249

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 10

ER -